<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8530">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00828295</url>
  </required_header>
  <id_info>
    <org_study_id>PALO-07-29</org_study_id>
    <nct_id>NCT00828295</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric Patients</brief_title>
  <official_title>A Multicenter, Double-blind, Randomized, Parallel Group, Stratified Study to Assess the Safety and Efficacy of Single IV Doses of Palonosetron to Prevent Postoperative Nausea and Vomiting in Pediatric Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinn Healthcare SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helsinn Healthcare SA</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Russia: Ethics Committee</authority>
    <authority>Russia: Ministry of Health of the Russian Federation</authority>
    <authority>Russia: Pharmacological Committee, Ministry of Health</authority>
    <authority>Ukraine: Ministry of Health</authority>
    <authority>Ukraine: State Pharmacological Center - Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to assess the safety and efficacy of two doses of IV
      palonosetron each administered as a single dose for the prevention of postoperative nausea
      and vomiting through 72 hours postoperatively in children aged 28 days up to 16 years
      inclusive undergoing surgical procedures requiring general endotracheal inhalation
      anesthesia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Proportion of Patients With no Emetic Episodes in the Overall Time Period 0-72 Hours Post-operatively</measure>
    <time_frame>0-72 hours post-operatively</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Complete Response 0-24 Hours</measure>
    <time_frame>0-24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Complete Response defined as no vomiting, no retching, and no use of rescue medication</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Postoperative Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>1 mcg/kg arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose IV Palonosetron 1 mcg/kg (up to a maximum total dose of 0.075 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 mcg/kg arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose IV Palonosetron 3 mcg/kg (up to a maximum total dose of 0.25 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>palonosetron</intervention_name>
    <description>palonosetron IV 1 mcg/kg</description>
    <arm_group_label>1 mcg/kg arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>palonosetron</intervention_name>
    <description>palonosetron 3mcg/kg IV</description>
    <arm_group_label>3 mcg/kg arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        MAIN INCLUSION CRITERIA

          -  Male or female patient aged more than 28 days (full term) up to and including 16
             years.

          -  Inpatient scheduled to undergo surgical procedures requiring general endotracheal
             anesthesia, including:

               -  ear, nose and throat surgery;

               -  eye surgery;

               -  orchidopexy;

               -  plastic reconstructive surgery;

               -  herniorraphy;

               -  orthopedic surgery).

          -  American Society of Anesthesiologists (ASA) physical status I, II or III.

          -  Patient scheduled to receive nitrous oxide during the maintenance phase of
             anesthesia.

          -  Patient scheduled to be hospitalized for at least 72 hours after wake up of surgery

          -  For female of childbearing potential: the patient and her parent(s)/legal guardian(s)
             were counseled on the importance of not becoming pregnant before or during the study
             and the patient must have a negative pregnancy test at the pre-treatment visit and at
             the study treatment visit.

        MAIN EXCLUSION CRITERIA

          -  For infant aged more than 12 months: a history of gastro-esophageal reflux.

          -  For patient aged 28 days to 6 years: patient who received any investigational drugs
             within 90 days prior to Day 1. For patient aged 6 up to 16 years inclusive: patient
             who received any investigational drugs within 30 days prior to Day 1.

          -  Patient scheduled to undergo emergency surgery.

          -  Patient scheduled to receive regional (spinal) anesthesia in conjunction with general
             endotracheal anesthesia.

          -  Patient scheduled to receive propofol during the maintenance phase of anesthesia.

          -  Patient with vomiting from any organic cause.

          -  Any drug with a potential anti-emetic effect within 24 hours prior to the
             administration of anesthesia.

          -  Any vomiting, retching, or nausea in the 24 hours preceding the administration of
             anesthesia.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Federal State Institution Central Research Institute of Traumatology and Orthopedics n.a. N.N. Priorov under the Federal Agency for High-Tech Medical Care</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Institution Moscow Research Institute of Pediatrics and Pediatric Surgery under the Federal Agency for High-Tech Medical Care</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Institution St. Petersburg Research Institute of Ear, Throat, Nose and Speech under the Federal Agency for High-Tech Medical Care</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Higher Educational Institution: &quot;St. Petersburg State Pediatric Medical Academy under the Federal Agency for Healthcare and Social Development&quot;</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution 'Regional Pediatric Clinical Hospital'</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cherkassy Regional Hospital, Pediatric Surgery Department</name>
      <address>
        <city>Cherkassy</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Children's Clinical Hospital. Dnipropetrovsk State Medical Academy, Pediatric Surgery Department</name>
      <address>
        <city>Dnipropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M.Gorkyi Donetsk National Medical University, Pediatric Surgery Department; Children's Regional Clinical Hospital</name>
      <address>
        <city>Donetsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Children's Hospital, ENT Department, Ivano-Frankivsk State Medical University, ENT Department</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specialized Children's Hospital &quot;OKHMATDYT&quot;, Orthopedics and Traumatology Department, O.O. Bohomolets National Medical University, Pediatric Surgery Department</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ukrainian Specialized Children's Hospital &quot;OKHMATDYT&quot;, Anesthesiology and Intensive Care Department, P.L. Shupyk National Medical Academy of Postgraduate Education, Pediatric Anesthesiology and Intensive Care Department</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ukrainian Specialized Children's Hospital &quot;OKHMATDYT&quot;, ENT Department, P.L. Shupyk National Medical Academy of Postgraduate Education, Pediatric ENT Department</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Clinical Hospital &quot;OKHMATDYT&quot;, Institute of Congenital Pathology under the Academy of Medical Sciences of Ukraine</name>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <lastchanged_date>March 17, 2015</lastchanged_date>
  <firstreceived_date>January 22, 2009</firstreceived_date>
  <firstreceived_results_date>June 27, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Postoperative Nausea and Vomiting</keyword>
  <keyword>palonosetron</keyword>
  <keyword>pediatric</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Palonosetron</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First patient enrolled: 19 August 2008. Last patient completed: 27 December 2008.
A total of 12 Investigators from two countries (Russia and Ukraine) participated in the study. The study was conducted at 4 sites in Russia and 8 sites in Ukraine.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>1 mcg/kg Arm</title>
          <description>Single dose IV Palonosetron 1 mcg/kg (up to a maximum total dose of 0.075 mg)
palonosetron: palonosetron IV 1 mcg/kg</description>
        </group>
        <group group_id="P2">
          <title>3 mcg/kg Arm</title>
          <description>Single dose IV Palonosetron 3 mcg/kg (up to a maximum total dose of 0.25 mg)
palonosetron: palonosetron 3mcg/kg IV</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1 mcg/kg Arm</title>
          <description>Single dose IV Palonosetron 1 mcg/kg (up to a maximum total dose of 0.075 mg)
palonosetron: palonosetron IV 1 mcg/kg</description>
        </group>
        <group group_id="B2">
          <title>3 mcg/kg Arm</title>
          <description>Single dose IV Palonosetron 3 mcg/kg (up to a maximum total dose of 0.25 mg)
palonosetron: palonosetron 3mcg/kg IV</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="75"/>
                <measurement group_id="B2" value="75"/>
                <measurement group_id="B3" value="150"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;2 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
                <measurement group_id="B2" value="4"/>
                <measurement group_id="B3" value="7"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>2 to &lt;6 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="18"/>
                <measurement group_id="B2" value="16"/>
                <measurement group_id="B3" value="34"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>6 to &lt;12 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="29"/>
                <measurement group_id="B2" value="33"/>
                <measurement group_id="B3" value="62"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>12 to &lt;17 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="25"/>
                <measurement group_id="B2" value="22"/>
                <measurement group_id="B3" value="47"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="29"/>
                <measurement group_id="B2" value="29"/>
                <measurement group_id="B3" value="58"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="46"/>
                <measurement group_id="B2" value="46"/>
                <measurement group_id="B3" value="92"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>American Indian or Alaska Native</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Native Hawaiian or Other Pacific Islander</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black or African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="75"/>
                <measurement group_id="B2" value="75"/>
                <measurement group_id="B3" value="150"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>More than one race</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Ukraine</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="48"/>
                <measurement group_id="B2" value="49"/>
                <measurement group_id="B3" value="97"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Russian Federation</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="27"/>
                <measurement group_id="B2" value="26"/>
                <measurement group_id="B3" value="53"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Patients With no Emetic Episodes in the Overall Time Period 0-72 Hours Post-operatively</title>
        <time_frame>0-72 hours post-operatively</time_frame>
        <safety_issue>No</safety_issue>
        <population>The Full Analysis Set (FAS) included all randomized patients, who received the study drug, had general anesthesia and surgery. Following the intent-to-treat principle, patients were assigned to the study treatment group according to the treatment to which they were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>1 mcg/kg Arm</title>
            <description>Single dose IV Palonosetron 1 mcg/kg (up to a maximum total dose of 0.075 mg)
palonosetron: palonosetron IV 1 mcg/kg</description>
          </group>
          <group group_id="O2">
            <title>3 mcg/kg Arm</title>
            <description>Single dose IV Palonosetron 3 mcg/kg (up to a maximum total dose of 0.25 mg)
palonosetron: palonosetron 3mcg/kg IV</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="75"/>
                  <measurement group_id="O2" value="75"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Proportion of Patients With no Emetic Episodes in the Overall Time Period 0-72 Hours Post-operatively</title>
            <units>percentage of patients</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="88.0" lower_limit="78.4" upper_limit="94.4"/>
                  <measurement group_id="O2" value="84.0" lower_limit="73.7" upper_limit="91.4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Complete Response 0-24 Hours</title>
        <description>Complete Response defined as no vomiting, no retching, and no use of rescue medication</description>
        <time_frame>0-24 hours</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>1 mcg/kg Arm</title>
            <description>Single dose IV Palonosetron 1 mcg/kg (up to a maximum total dose of 0.075 mg)
palonosetron: palonosetron IV 1 mcg/kg</description>
          </group>
          <group group_id="O2">
            <title>3 mcg/kg Arm</title>
            <description>Single dose IV Palonosetron 3 mcg/kg (up to a maximum total dose of 0.25 mg)
palonosetron: palonosetron 3mcg/kg IV</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="75"/>
                  <measurement group_id="O2" value="75"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Proportion of Patients With Complete Response 0-24 Hours</title>
            <description>Complete Response defined as no vomiting, no retching, and no use of rescue medication</description>
            <units>percentage of patients</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="88.0" lower_limit="78.4" upper_limit="94.4"/>
                  <measurement group_id="O2" value="84.0" lower_limit="73.7" upper_limit="91.4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During the study, all adverse events were recorded and Patients stayed in the study for 22 days as a maximum. Duration of the safety follow up was 14 days after the patient completed the study for non Serious adverse events.</time_frame>
      <desc>Serious AEs were followed up until resolution/or reached a stable condition/or until subject lost to follow-up, Safety Set/SAF included all randomized patients assigned to treatment group according to actual treatment received. SAF had 74 and 76 patients/1 mcg/kg 3 mcg/kg group respectively/since one patient randomized 1 mcg/kg was treated 3 mcg/kg</desc>
      <group_list>
        <group group_id="E1">
          <title>1 mcg/kg Arm</title>
          <description>Single dose IV Palonosetron 1 mcg/kg (up to a maximum total dose of 0.075 mg)
palonosetron: palonosetron IV 1 mcg/kg</description>
        </group>
        <group group_id="E2">
          <title>3 mcg/kg Arm</title>
          <description>Single dose IV Palonosetron 3 mcg/kg (up to a maximum total dose of 0.25 mg)
palonosetron: palonosetron 3mcg/kg IV</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="74"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Rhinalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Salvatore Chessari</name_or_title>
      <organization>Helsinn Healthcare SA</organization>
      <phone>+41 91 985 21 21</phone>
      <email>salvatore.chessari@helsinn.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
